Ocular allergy: Recognizing and diagnosing hypersensitivity disorders of the ocular surface

Allergy: European Journal of Allergy and Clinical Immunology

Volumn 67, Issue 11, 2012, Pages 1327-1337

  Leonardi, A ^a   Bogacka, E ^b   Fauquert, J L ^c   Kowalski, M L ^d   Groblewska, A ^e   Jedrzejczak Czechowicz, M ^d   Doan, S ^f   Marmouz, F ^g   Demoly, P ^h   Delgado, L ⁱ  

^a UNIVERSITY OF PADOVA   (Italy)

^b WROCLAW MEDICAL UNIVERSITY   (Poland)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d MEDICAL UNIVERSITY OF LODZ   (Poland)

^e POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^f BICHAT HOSPITAL   (France)

^g Pole Sanitaire du Vexin   (France)

^h HÔPITAL ARNAUD DE VILLENEUVE   (France)

ⁱ University of Porto   (Portugal)

Author keywords

allergy; diagnosis; keratoconjunctivitis; ocular; treatment

Indexed keywords

ANTIHISTAMINIC AGENT; AZELASTINE; CALCINEURIN INHIBITOR; CORTICOSTEROID; CROMOGLYCATE DISODIUM; DESONIDE; EOSINOPHIL CATIONIC PROTEIN; EPINASTINE; FLUOROMETHOLONE; FLUTICASONE FUROATE; IMMUNOGLOBULIN E; INTERLEUKIN 4; KETOTIFEN; LODOXAMIDE; LOTEPREDNOL; MEDRYSONE; MOMETASONE FUROATE; NEDOCROMIL; NONSTEROID ANTIINFLAMMATORY AGENT; OLOPATADINE; PEMIROLAST; PIMECROLIMUS; RIMEXOLONE; TACROLIMUS; VASOCONSTRICTOR AGENT;

ABSENCE OF SIDE EFFECTS; ANTICHOLINERGIC EFFECT; ARTICLE; ATOPIC KERATOCONJUNCTIVITIS; CATARACT; CD4+ T LYMPHOCYTE; CELL ADHESION; COMPRESSION; CONTACT BLEPHAROCONJUNCTIVITIS; CONTACT LENS; DANDER; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE SEVERITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRY EYE; EYE ALLERGY; EYE PROTECTIVE DEVICE; EYE REDNESS; EYELID EDEMA; GIANT PAPILLARY CONJUNCTIVITIS; HERPES SIMPLEX KERATITIS; HOUSE DUST ALLERGY; HUMAN; KERATOCONJUNCTIVITIS; KERATOCONUS; MOULD; NOMENCLATURE; NONHUMAN; OCCUPATIONAL ALLERGY; OCULAR PRURITUS; PATHOGENESIS; PATHOPHYSIOLOGY; PATIENT EDUCATION; PERENNIAL ALLERGIC CONJUNCTIVITIS; PHOTOPHOBIA; PRIORITY JOURNAL; PUNCTATE KERATITIS; RETINA DETACHMENT; SEASONAL ALLERGIC CONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TH2 CELL; VERNAL CONJUNCTIVITIS;

CONJUNCTIVITIS, ALLERGIC; HUMANS;

EID: 84867519408     PISSN: 01054538     EISSN: 13989995     Source Type: Journal    
DOI: 10.1111/all.12009     Document Type: Article

References (78)

1. Petricek I, Prost M, Popova A,. The differential diagnosis of red eye: a survey of medical practitioners from Eastern Europe and the Middle East. Ophthalmologica 2006; 220: 229-237.
2. Smith AF, Pitt AD, Rodruiguez AE, Alio JL, Marti N, Teus M, et al. The economic and quality of life impact of seasonal allergic conjunctivitis in a Spanish setting. Ophthalmic Epidemiol 2005; 12: 233-242.
3. Pitt AD, Smith AF, Lindsell L, Voon LW, Rose PW, Bron AJ,. Economic and quality-of-life impact of seasonal allergic conjunctivitis in Oxfordshire. Ophthalmic Epidemiol 2004; 11: 17-33.
4. Palmares J, Delgado L, Cidade M, Quadrado MJ, Filipe HP,. Allergic conjunctivitis: a national cross-sectional study of clinical characteristics and quality of life. Eur J Ophthalmol 2010; 20: 257-264.
5. Harbour R, Miller J,. A new system for grading recommendations in evidence based guidelines. BMJ 2001; 323: 334-336.
6. Johansson SG, Hourihane JO, Bousquet J, Bruijnzeel-Koomen C, Dreborg S, Haahtela T, et al. A revised nomenclature for allergy. An EAACI position statement from the EAACI nomenclature task force. Allergy 2001; 56: 813-824.
7. Johansson SG, Bieber T, Dahl R, Friedmann PS, Lanier BQ, Lockey RF, et al. Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003. J Allergy Clin Immunol 2004; 113: 832-836.
8. Leonardi A, De Dominicis C, Motterle L,. Immunopathogenesis of ocular allergy: a schematic approach to different clinical entities. Curr Opin Allergy Clin Immunol 2007; 7: 429-435.
9. Brozek JL, Bousquet J, Baena-Cagnani CE, Bonini S, Canonica GW, Casale TB, et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476.
10. Uchio E, Kimura R, Migita H, Kozawa M, Kadonosono K,. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol 2008; 246: 291-296.
11. Diallo JS,. Tropical endemic limboconjunctivitis. Rev Int Trach Pathol Ocul Trop Subtrop 1976; 53: 71-80.
12. Limsuwan T, Demoly P,. Acute symptoms of drug hypersensitivity (urticaria, angioedema, anaphylaxis, anaphylactic shock). Med Clin North Am 2010; 94: 691-710.
13. Wittczak T, Pas-Wyroilak A, Palczynski C,. Occupational allergic conjunctivitis. Med Pr 2007; 58: 125-130.
14. Baudouin C,. Allergic reaction to topical eyedrops. Curr Opin Allergy Clin Immunol 2005; 5: 459-463.
15. Ait-Khaled N, Pearce N, Anderson HR, Ellwood P, Montefort S, Shah J,. Global map of the prevalence of symptoms of rhinoconjunctivitis in children: The International Study of Asthma and Allergies in Childhood (ISAAC) Phase Three. Allergy 2009; 64: 123-148.
16. Gradman J, Wolthers OD,. Allergic conjunctivitis in children with asthma, rhinitis and eczema in a secondary outpatient clinic. Pediatr Allergy Immunol 2006; 17: 524-526.
17. Singh K, Axelrod S, Bielory L,. The epidemiology of ocular and nasal allergy in the United States, 1988-1994. J Allergy Clin Immunol 2010; 126: 778-783.
18. Meltzer EO,. The prevalence and medical and economic impact of allergic rhinitis in the United States. J Allergy Clin Immunol 1997; 2 (6 Pt 2): S805-S828.
19. Bielory L,. Allergic and immunologic disorders of the eye. Part II: ocular allergy. J Allergy Clin Immunol 2000; 106: 1019-1032.
20. Ciprandi G, Cirillo I, Vizzaccaro A, Tosca M, Passalacqua G, Pallestrini E, et al. Seasonal and perennial allergic rhinitis: is this classification adherent to real life? Allergy 2005; 60: 882-887.
21. Bremond-Gignac D, Donadieu J, Leonardi A, Pouliquen P, Doan S, Chiambarretta F, et al. Prevalence of vernal keratoconjunctivitis: a rare disease? Br J Ophthalmol 2008; 92: 1097-1102.
22. Abelson MB, Chambers WA, Smith LM,. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990; 108: 84-88.
23. Leonardi A, Borghesan F, Faggian D, Depaoli M, Secchi AG, Plebani M,. Tear and serum soluble leukocyte activation markers in conjunctival allergic diseases. Am J Ophthalmol 2000; 129: 151-158.
24. Anderson DF, Zhang S, Bradding P, McGill JI, Holgate ST, Roche WR,. The relative contribution of mast cell subsets to conjunctival TH2-like cytokines. Invest Ophthalmol Vis Sci 2001; 42: 995-1001.
25. Fukushima A, Yamaguchi T, Ishida W, Fukata K, Ueno H,. Role of VLA-4 in the development of allergic conjunctivitis in mice. Mol Vis 2006; 12: 310-317.
26. Miyazaki D, Nakamura T, Toda M, Cheung-Chau KW, Richardson RM, Ono SJ,. Macrophage inflammatory protein-1alpha as a costimulatory signal for mast cell-mediated immediate hypersensitivity reactions. J Clin Invest 2005; 115: 434-442.
27. Cook EB, Stahl JL, Lowe L, Chen R, Morgan E, Wilson J, et al. Simultaneous measurement of six cytokines in a single sample of human tears using microparticle-based flow cytometry: allergics vs. non-allergics. J Immunol Methods 2001; 254: 109-118.
28. Hughes JL, Lackie PM, Wilson SJ, Church MK, McGill JI,. Reduced structural proteins in the conjunctival epithelium in allergic eye disease. Allergy 2006; 61: 1268-1274.
29. Leonardi A,. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002; 21: 319-339.
30. Abu El-Asrar AM, Fatani RA, Missotten L, Geboes K,. Expression of CD23/CD21 and CD40/CD40 ligand in vernal keratoconjunctivitis. Eye (Lond) 2001; 15 (Pt 2): 217-224.
31. Leonardi A, Curnow SJ, Zhan H, Calder VL,. Multiple cytokines in human tear specimens in seasonal and chronic allergic eye disease and in conjunctival fibroblast cultures. Clin Exp Allergy 2006; 36: 777-784.
32. Leonardi A, Sathe S, Bortolotti M, Beaton A, Sack R,. Cytokines, matrix metalloproteases, angiogenic and growth factors in tears of normal subjects and vernal keratoconjunctivitis patients. Allergy 2009; 64: 710-717.
33. Shoji J, Inada N, Sawa M,. Antibody array-generated cytokine profiles of tears of patients with vernal keratoconjunctivitis or giant papillary conjunctivitis. Jpn J Ophthalmol 2006; 50: 195-204.
34. Leonardi A, Brun P, Abatangelo G, Plebani M, Secchi AG,. Tear levels and activity of matrix metalloproteinase (MMP)-1 and MMP-9 in vernal keratoconjunctivitis. Invest Ophthalmol Vis Sci 2003; 44: 3052-3058.
35. Manzouri B, Ohbayashi M, Leonardi A, Larkin DF, Ono SJ,. Characterization of dendritic cell phenotype in allergic conjunctiva: increased expression of Fc(epsilon)RI, the high-affinity receptor for immunoglobulin E. Eye (Lond) 2009; 23: 2099-2104.
36. Leonardi A, Busca F, Motterle L, Cavarzeran F, Fregona IA, Plebani M, et al. Case series of 406 vernal keratoconjunctivitis patients: a demographic and epidemiological study. Acta Ophthalmol Scand 2006; 84: 406-410.
37. Kumagai N, Fukuda K, Fujitsu Y, Yamamoto K, Nishida T,. Role of structural cells of the cornea and conjunctiva in the pathogenesis of vernal keratoconjunctivitis. Prog Retin Eye Res 2006; 25: 165-187.
38. Motterle L, Diebold Y, Enriquez de Salamanca A, Saez V, Garcia-Vazquez C, Stern ME, et al. Altered expression of neurotransmitter receptors and neuromediators in vernal keratoconjunctivitis. Arch Ophthalmol 2006; 124: 462-468.
39. Bonini S,. Atopic keratoconjunctivitis. Allergy 2004; 59 (Suppl 78): 71-73.
40. Nivenius E, Montan PG, Chryssanthou E, Jung K, van Hage-Hamsten M, van der Ploeg I,. No apparent association between periocular and ocular microcolonization and the degree of inflammation in patients with atopic keratoconjunctivitis. Clin Exp Allergy 2004; 34: 725-730.
41. Yamagami S, Ebihara N, Amano SY,. Chemokine receptor gene expression in giant papillae of atopic keratoconjunctivitis. Mol Vis 2005; 11: 192-200.
42. Dogru M, Okada N, Asano-Kato N, Igarashi A, Fukagawa K, Shimazaki J, et al. Alterations of the ocular surface epithelial mucins 1, 2, 4 and the tear functions in patients with atopic keratoconjunctivitis. Clin Exp Allergy 2006; 36: 1556-1565.
43. Bonini S, Micera A, Iovieno A, Lambiase A,. Expression of Toll-like receptors in healthy and allergic conjunctiva. Ophthalmology 2005; 112: 1528.
44. Thakur A, Willcox MD,. Contact lens wear alters the production of certain inflammatory mediators in tears. Exp Eye Res 2000; 70: 255-259.
45. Vieira T, Lopes C, Pereira AM, Araujo L, Moreira A, Delgado L,. Microarray based IgE detection in poly-sensitized allergic patients with suspected food allergy-an approach in four clinical cases. Allergol Immunopathol (Madr) 2012; 40: 172-180.
46. Mortemousque B, Fauquert JL, Chiambaretta F, Demoly P, Helleboid L, Creuzot-Garcher C, et al. Conjunctival provocation test: recommendations. J Fr Ophtalmol 2006; 29: 837-846.
47. Leonardi A, Battista MC, Gismondi M, Fregona IA, Secchi AG,. Antigen sensitivity evaluated by tear-specific and serum-specific IgE, skin tests, and conjunctival and nasal provocation tests in patients with ocular allergic disease. Eye 1993; 7 (Pt 3): 461-464.
48. Bourke J, Coulson I, English J,. Guidelines for care of contact dermatitis. Br J Dermatol 2001; 145: 877-885.
49. Le Coz CJ, Sasseville D,. Interpretation and relevance of patch testing: false-positive and false-negative test reactions, compound allergy, cross-sensitivity. Ann Dermatol Venereol 2009; 136: 610-616.
50. Leonardi A,. In-vivo diagnostic measurements of ocular inflammation. Curr Opin Allergy Clin Immunol 2005; 5: 464-472.
51. Mimura T, Usui T, Mori M, Funatsu H, Noma H, Yamamoto H, et al. Relation Between Total Tear IgE and Specific Serum IgE in Seasonal Allergic Conjunctivitis. Cornea 2011; 30: 790-795.
52. Batellier L, Poilane C, Rault J, Chaumeil C, Scat Y,. Measurement of total IgE in tears: the adaptation of an immunoenzyme technique and the value of investigating locally produced IgE in the diagnosis of chronic conjunctivitis. Ann Biol Clin (Paris) 1999; 57: 469-473.
53. Leonardi A, Jose PJ, Zhan H, Calder VL,. Tear and mucus eotaxin-1 and eotaxin-2 in allergic keratoconjunctivitis. Ophthalmology 2003; 110: 487-492.
54. Hu Y, Matsumoto Y, Adan ES, Dogru M, Fukagawa K, Tsubota K, et al. Corneal in vivo confocal scanning laser microscopy in patients with atopic keratoconjunctivitis. Ophthalmology 2008; 115: 2004-2012.
55. Leonardi A, Lazzarini D, Bortolotti M, Piliego F, Midena E, Fregona I,. Corneal Confocal Microscopy in Patients with Vernal Keratoconjunctivitis. Ophthalmology 2012; 119: 509-515.
56. Bielory L, Lien KW, Bigelsen S,. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005; 65: 215-228.
57. Abelson MB, McLaughlin JT, Gomes PJ,. Antihistamines in ocular allergy: are they all created equal? Curr Allergy Asthma Rep 2011; 11: 205-211.
58. Verin P, Easty DL, Secchi A, Ciprandi G, Partouche P, Nemeth-Wasmer G, et al. Clinical evaluation of twice-daily emedastine 0.05% eye drops (Emadine eye drops) versus levocabastine 0.05% eye drops in patients with allergic conjunctivitis. Am J Ophthalmol 2001; 131: 691-698.
59. Cook EB, Stahl JL, Barney NP, Graziano FM,. Mechanisms of antihistamines and mast cell stabilizers in ocular allergic inflammation. Curr Drug Targets Inflamm Allergy 2002; 1: 167-180.
60. Yanni JM, Miller ST, Gamache DA, Spellman JM, Xu S, Sharif NA,. Comparative effects of topical ocular anti-allergy drugs on human conjunctival mast cells. Ann Allergy Asthma Immunol 1997; 79: 541-545.
61. Borazan M, Karalezli A, Akova YA, Akman A, Kiyici H, Erbek SS,. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol 2009; 87: 549-554.
62. Ballas Z, Blumenthal M, Tinkelman DG, Kriz R, Rupp G,. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993; 38 (Suppl): 141-148.
63. Tauber J, Raizman MB, Ostrov CS, Laibovitz RA, Abelson MB, Betts JG, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1998; 14: 137-145.
64. Bielory L, Chun Y, Bielory BP, Canonica GW,. Impact of mometasone furoate nasal spray on individual ocular symptoms of allergic rhinitis: a meta-analysis. Allergy 2011; 66: 686-693.
65. Kaiser HB, Naclerio RM, Given J, Toler TN, Ellsworth A, Philpot EE,. Fluticasone furoate nasal spray: a single treatment option for the symptoms of seasonal allergic rhinitis. J Allergy Clin Immunol 2007; 119: 1430-1437.
66. Lightman S, Scadding GK,. Should Intranasal Corticosteroids Be Used for the Treatment of Ocular Symptoms of Allergic Rhinoconjunctivitis? A Review of Their Efficacy and Safety Profile Int Arch Allergy Immunol 2012; 158: 317-325.
67. Pucci N, Novembre E, Cianferoni A, Lombardi E, Bernardini R, Caputo R, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002; 89: 298-303.
68. Utine CA, Stern M, Akpek EK,. Clinical review: topical ophthalmic use of cyclosporin A. Ocul Immunol Inflamm 2010; 18: 352-361.
69. Daniell M, Constantinou M, Vu HT, Taylor HR,. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006; 90: 461-464.
70. Lambiase A, Leonardi A, Sacchetti M, Deligianni V, Sposato S, Bonini S,. Topical cyclosporine prevents seasonal recurrences of vernal keratoconjunctivitis in a randomized, double-masked, controlled 2-year study. J Allergy Clin Immunol 2011; 128: 896-897.
71. Ebihara N, Ohashi Y, Uchio E, Okamoto S, Kumagai N, Shoji J, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009; 25: 365-372.
72. Rikkers SM, Holland GN, Drayton GE, Michel FK, Torres MF, Takahashi S,. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003; 135: 297-302.
73. Vichyanond P, Tantimongkolsuk C, Dumrongkigchaiporn P, Jirapongsananuruk O, Visitsunthorn N, Kosrirukvongs P,. Vernal keratoconjunctivitis: Result of a novel therapy with 0.1% topical ophthalmic FK-506 ointment. J Allergy Clin Immunol 2004; 113: 355-358.
74. Attas-Fox L, Barkana Y, Iskhakov V, Rayvich S, Gerber Y, Morad Y, et al. Topical tacrolimus 0.03% ointment for intractable allergic conjunctivitis: an open-label pilot study. Curr Eye Res 2008; 33: 545-549.
75. Chen SL, Yan J, Wang FS,. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials. J Dermatolog Treat 2010; 21: 144-156.
76. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham S,. Sublingual immunotherapy for treating allergic conjunctivitis. Cochrane Database Syst Rev 2011; 7: CD007685.
77. Frolund L, Durham SR, Calderon M, Emminger W, Andersen JS, Rask P, et al. Sustained effect of SQ-standardized grass allergy immunotherapy tablet on rhinoconjunctivitis quality of life. Allergy 2010; 65: 753-757.
78. Calderon MA, Penagos M, Sheikh A, Canonica GW, Durham SR,. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy 2011; 41: 1263-1272.